uniQure's (QURE) HOPE B Data In-Line With Expectations, Potential Peak Royalties of $485M - Analyst

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to uniQure's (QURE) HOPE B Data In-Line With Expectations, Potential Peak Royalties of $485M - Analyst

uniQure (QURE), CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

December 9, 2021 7:07 AM EST

CSL Behring, a global biotherapeutics leader, and uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that etranacogene dezaparvovec, an investigational adeno-associated... More